EditCo Bio, Inc., with the support of life sciences investment firm Telegraph Hill Partners, has acquired Synthego's engineered cell solutions business. This acquisition enables EditCo to further its mission of providing high-quality, easily accessible reagents for cellular research, with a focus on the rapidly expanding CRISPR market.